Prognosis and treatment of macular bleeding in neovascular age-related macular degeneration

被引：0
|
作者：
Agostini, H. T. [1 ]
Bopp, S. [2 ]
Feltgen, N. [3 ]
机构：
[1] Univ Klinikum Freiburg, Klin Augenheilkunde, Killianstr 5, D-79106 Freiburg, Germany
[2] Tagesklin, Augenabt, Univ Allee, Bremen, Germany
[3] Univ Klinikum Gottingen, Univ Augenklin, Gottingen, Germany
来源：
OPHTHALMOLOGE | 2017年 / 114卷 / 05期
关键词：
Subretinal hemorrhage; Coagulation; Vitrectomy; Visual deterioration; Intravitral injection; TISSUE-PLASMINOGEN ACTIVATOR; SUBMACULAR HEMORRHAGE; NATURAL-HISTORY; SUBRETINAL HEMORRHAGE; CO-APPLICATION; BEVACIZUMAB; COMPATIBILITY;
D O I：
10.1007/s00347-017-0487-x
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Macular bleeding is associated with an acute loss of visual function and is frequently a complication of neovascular age-related macular degeneration. Blood degradation products can lead to permanent retinal neuronal damage over time. The extent of the bleeding is correlated to the coagulation status of the patient. The treatment strategy depends on the age, size and exact location of the bleeding. The spectrum of therapeutic options ranges from watchful waiting to large scale vitrectomy with removal of subretinal mass bleeding.
引用
收藏
页码：476 / 480
页数：5
相关论文
共 50 条
  • [1] Macular translocation for neovascular age-related macular degeneration
    Eandi, Chiara M.
    Giansanti, Fabrizio
    Virgili, Gianni
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [2] Neovascular Age-Related Macular Degeneration
    Veritti, Daniele
    Sarao, Valentina
    Lanzetta, Paolo
    [J]. OPHTHALMOLOGICA, 2012, 227 : 11 - 20
  • [3] The natural history and prognosis of neovascular age-related macular degeneration
    Wong, Tien
    Chakravarthy, Usha
    Klein, Ronald
    Mitchell, Paul
    Zlateva, Gergana
    Buggage, Ronald
    Fahrbach, Kyle
    Probst, Corey
    Sledge, Isabella
    [J]. OPHTHALMOLOGY, 2008, 115 (01) : 116 - 126
  • [4] Guidance for the treatment of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Richard, Gisbert
    Augustin, Albert
    Aylward, William G.
    Bandello, Francesco
    Corcostegui, Borja
    Cunha-Vaz, Jose
    Gaudric, Alain
    Leys, Anita
    Schlingemann, Rainier O.
    [J]. ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (05): : 486 - 494
  • [5] Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
    Pitlick, Jamie M.
    Vecera, Kayla F.
    Barnes, Kylie N.
    Reski, John W.
    Forinash, Alicia B.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 290 - 296
  • [6] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Verner-Cole, E. A.
    Davis, S. J.
    Lauer, A. K.
    [J]. DRUGS OF TODAY, 2012, 48 (05) : 317 - 329
  • [7] Advances in the treatment of neovascular age-related macular degeneration
    Lanzetta, Paolo
    [J]. EJHP PRACTICE, 2008, 14 (06): : 17 - 20
  • [8] TREATMENT PATTERNS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Dugel, P. U.
    Arnold, R. J.
    Layton, A. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A149 - A149
  • [9] Treatment Approaches for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Almony, Arghavan
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (06): : S81 - S89
  • [10] Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Desideri, Lorenzo Ferro
    Traverso, Carlo Enrico
    Nicolo, Massimo
    Munk, Marion R.
    [J]. PHARMACEUTICS, 2023, 15 (05)
12345